Seminars in Oncology
Volume 36, Issue 3 , Pages 227-236 , June 2009

Sarcoma in the Young Adult Population: An International View

  • Hatem Soliman

      Affiliations

    • Department of Oncologic Sciences, University of South Florida Moffitt Cancer Center and Research Institute, Tampa, FL
    • Corresponding Author InformationAddress correspondence to Hatem Soliman, MD, Moffitt Cancer Center and Research Institute, BR Prog, 12902 Magnolia Dr, Tampa, FL 33612
    • ,
  • Andrea Ferrari

      Affiliations

    • Pediatric Oncology Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy
    • ,
  • David Thomas

      Affiliations

    • Adolescent and Young Adult Cancer Service, Peter MacCallum Cancer Centre, Victoria, Australia

References 

  1. Bleyer A. Young adult oncology: the patients and their survival challenges. CA Cancer J Clin. 2007;57:242–255
  2. Bleyer A, Barr R, Hayes-Lattin B, Thomas D, Ellis C, Anderson B. The distinctive biology of cancer in adolescents and young adults. Nat Rev. 2008;8:288–298
  3. Bleyer A, Budd T, Montello M. Adolescents and young adults with cancer: the scope of the problem and criticality of clinical trials. Cancer. 2006;107(Suppl):1645–1655
  4. Bleyer A, Montello M, Budd T, Saxman S. National survival trends of young adults with sarcoma: lack of progress is associated with lack of clinical trial participation. Cancer. 2005;103(9):1891–1897
  5. Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M. Cancer incidence in five continents. vol. IX. Lyon: IARC Scientific Publications; 2007;
  6. Henderson TO, Whitton J, Stovall M, Mertens AC, Mitby P, Friedman D, et al. Secondary sarcomas in childhood cancer survivors: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2007;99:300–308
  7. Ji J, Hemminki K. Incidence of multiple primary malignancies among patients with bone cancers in Sweden. J Cancer Res Clin Oncol. 2006;132:529–535
  8. Hoppin JA, Tolbert PE, Herrick RF, Freedman DS, Ragsdale BD, Horvat KR, et al. Occupational chlorophenol exposure and soft tissue sarcoma risk among men aged 30-60 years. Am J Epidemiol. 1998;148:693–703
  9. Hoppin JA, Tolbert PE, Flanders WD, Zhang RH, Daniels DS, Ragsdale BD, et al. Occupational risk factors for sarcoma subtypes. Epidemiology. 1999;10:300–306Cambridge, Mass
  10. Zambon P, Ricci P, Bovo E, Casula A, Gattolin M, Fiore AR, et al. Sarcoma risk and dioxin emissions from incinerators and industrial plants: a population-based case-control study (Italy). Environ Health. 2007;6:19
  11. Gennaro V, Ceppi M, Crosignani P, Montanaro F. Reanalysis of updated mortality among vinyl and polyvinyl chloride workers: Confirmation of historical evidence and new findings. BMC Public Health. 2008;8:21
  12. Pyakurel P, Pak F, Mwakigonja AR, Kaaya E, Biberfeld P. KSHV/HHV-8 and HIV infection in Kaposi's sarcoma development. Infect Agent Cancer. 2007;2:4
  13. Dupont C, Vasseur E, Beauchet A, Aegerter P, Berthe H, de Truchis P, et al. Long-term efficacy on Kaposi's sarcoma of highly active antiretroviral therapy in a cohort of HIV-positive patients (CISIH 92. Centre d'information et de soins de l'immunodeficience humaine). AIDS. 2000;14:987–993
  14. Jones RL, Fisher C, Al-Muderis O, Judson IR. Differential sensitivity of liposarcoma subtypes to chemotherapy. Eur J Cancer. 2005;41:2853–2860
  15. Pervaiz N, Colterjohn N, Farrokhyar F, Tozer R, Figueredo A, Ghert M. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer. 2008;113:573–581
  16. Frustaci S, Gherlinzoni F, De Paoli A, Bonetti M, Azzarelli A, Comandone A, et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol. 2001;19:1238–1247
  17. Ferrari A, Casanova M. New concepts for the treatment of pediatric nonrhabdomyosarcoma soft tissue sarcomas. Expert Rev Anticancer Ther. 2005;5:307–318
  18. Verma S, Younus J, Stys-Norman D, Haynes AE, Blackstein M. Meta-analysis of ifosfamide-based combination chemotherapy in advanced soft tissue sarcoma. Cancer Treat Rev. 2008;34:339–347
  19. Schwab JH, Boland P, Guo T, Brennan MF, Singer S, Healey JH, et al. Skeletal metastases in myxoid liposarcoma: an unusual pattern of distant spread. Ann Surg Oncol. 2007;14:1507–1514
  20. Grosso F, Jones RL, Demetri GD, Judson IR, Blay JY, Le Cesne A, et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol. 2007;8:595–602
  21. Maki RG. Gemcitabine and docetaxel in metastatic sarcoma: past, present, and future. Oncologist. 2007;12:999–1006
  22. Hensley ML, Maki R, Venkatraman E, Geller G, Lovegren M, Aghajanian C, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol. 2002;20:2824–2831
  23. Hartmann JT, Mayer F, Schleicher J, Horger M, Huober J, Meisinger I, et al. Bendamustine hydrochloride in patients with refractory soft tissue sarcoma: a noncomparative multicenter phase 2 study of the German sarcoma group (AIO-001). Cancer. 2007;110:861–866
  24. Fanburg-Smith JC, Miettinen M. Angiomatoid “malignant” fibrous histiocytoma: a clinicopathologic study of 158 cases and further exploration of the myoid phenotype. Hum Pathol. 1999;30:1336–1343
  25. Remstein ED, Arndt CA, Nascimento AG. Plexiform fibrohistiocytic tumor: clinicopathologic analysis of 22 cases. Am J Surg Pathol. 1999;23:662–670
  26. Adam LR, Davison EV, Malcolm AJ, Pearson AD, Craft AW. Cytogenetic analysis of a congenital fibrosarcoma. Cancer Genet Cytogenet. 1991;52:37–41
  27. Albritton K, Ferrari A, Casanova M. Soft Tissue Sarcomas. In:  Bleyer A,  Duncan R editor. Cancer in Adolescents and Young Adults. Berlin: Springer; 2007;p. 185–199
  28. Ferrari A, Dileo P, Casanova M, Bertulli R, Meazza C, Gandola L, et al. Rhabdomyosarcoma in adults (A retrospective analysis of 171 patients treated at a single institution). Cancer. 2003;98:571–580
  29. Crist W, Gehan EA, Ragab AH, Dickman PS, Donaldson SS, Fryer C, et al. The Third Intergroup Rhabdomyosarcoma Study. J Clin Oncol. 1995;13:610–630
  30. El-Badry OM, Minniti C, Kohn EC, Houghton PJ, Daughaday WH, Helman LJ. Insulin-like growth factor II acts as an autocrine growth and motility factor in human rhabdomyosarcoma tumors. Cell Growth Differ. 1990;1:325–331
  31. Ferrari A, Gronchi A, Casanova M, Meazza C, Gandola L, Collini P, et al. Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institution. Cancer. 2004;101:627–634
  32. Lee SY, Obata Y, Yoshida M, Stockert E, Williamson B, Jungbluth AA, et al. Immunomic analysis of human sarcoma. Proc Natl Acad Sci U S A. 2003;100:2651–2656
  33. Ferner RE, Gutmann DH. International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. Cancer Res. 2002;62:1573–1577
  34. Maki RG, Awan RA, Dixon RH, Jhanwar S, Antonescu CR. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. Int J Cancer. 2002;100:623–626
  35. Cattelan AM, Calabro ML, De Rossi A, Aversa SM, Barbierato M, Trevenzoli M, et al. Long-term clinical outcome of AIDS-related Kaposi's sarcoma during highly active antiretroviral therapy. Int J Oncol. 2005;27:779–785
  36. Gill PS, Tulpule A, Espina BM, Cabriales S, Bresnahan J, Ilaw M, et al. Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi's sarcoma. J Clin Oncol. 1999;17:1876–1883
  37. Gill PS, Wernz J, Scadden DT, Cohen P, Mukwaya GM, von Roenn JH, et al Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol. 1996;14:2353–2364
  38. Miettinen M, Lasota J, Sobin LH. Gastrointestinal stromal tumors of the stomach in children and young adults: a clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases with long-term follow-up and review of the literature. Am J Surg Pathol. 2005;29:1373–1381
  39. Prakash S, Sarran L, Socci N, DeMatteo RP, Eisenstat J, Greco AM, et al. Gastrointestinal stromal tumors in children and young adults: a clinicopathologic, molecular, and genomic study of 15 cases and review of the literature. J Pediatr Hematol Oncol. 2005;27:179–187
  40. Swallow CJ, Catton CN. Local management of adult soft tissue sarcomas. Semin Oncol. 2007;34:256–269
  41. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472–480
  42. Holdsworth CH, Badawi RD, Manola JB, Kijewski MF, Israel DA, Demetri GD. CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor. AJR. 2007;189:W324–W330
  43. Van den Abbeele AD, Badawi RD. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur J Cancer. 2002;38(Suppl 5):S60–S65
  44. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368:1329–1338
  45. Scurr M, Judson I. How to treat the Ewing's family of sarcomas in adult patients. Oncologist. 2006;11:65–72
  46. Temple HT, Scully SP, O'Keefe RJ, Katapurum S, Mankin HJ. Clinical outcome of 38 patients with juxtacortical osteosarcoma. Clin Orthop Rel Res. 2000;373:208–217
  47. Lee JA, Kim MS, Kim DH, Lim JS, Park KD, Song WS, et al. Osteosarcoma developed in the period of maximal growth rate have inferior prognosis. J Pediatr Hematol Oncol. 2008;30:419–424
  48. Bielack S, Carrle D, Jost L. Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2008;19(Suppl 2):ii94–ii96
  49. Dantonello TM, Int-Veen C, Leuschner I, Schuck A, Furtwaengler R, Claviez A, et al. Mesenchymal chondrosarcoma of soft tissues and bone in children, adolescents, and young adults: experiences of the CWS and COSS study groups. Cancer. 2008;112:2424–2431
  50. Zeltzer LK. Cancer in adolescents and young adults psychosocial aspects (Long-term survivors). Cancer. 1993;71(Suppl):3463–3468
  51. Zebrack B, Bleyer A, Albritton K, Medearis S, Tang J. Assessing the health care needs of adolescent and young adult cancer patients and survivors. Cancer. 2006;107:2915–2923
  52. Meirow D, Nugent D. The effects of radiotherapy and chemotherapy on female reproduction. Hum Reprod Update. 2001;7:535–543
  53. Ferrari A, Montello M, Budd T, Bleyer A. The challenges of clinical trials for adolescents and young adults with cancer. Pediatr Blood Cancer. 2008;50(Suppl):1101–1104

 H.S. is supported by National Institutes of Health Grant No. 5K12CA087989-05 and D.T. is supported by a Victorian Cancer Agency Clinician Scientist Award.

PII: S0093-7754(09)00043-8

doi: 10.1053/j.seminoncol.2009.03.006

Seminars in Oncology
Volume 36, Issue 3 , Pages 227-236 , June 2009

Article Tools

* Image Usage & Resolution